Treating Newly Diagnosed Ph+ ALL! ICLUSIG (Ponatinib) Meets Primary Endpoint in Phase 3 Trial

Takeda Pharmaceutical Company Limited (Takeda) recently announced that the Phase 3 PhALLCON trial—a randomized, international, open-label, multicenter study—is evaluating the efficacy and safety of ponatinib in combination with low-intensity chemotherapy, compared with imatinib plus low-intensity chemotherapy, as a first-line treatment for adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).

The Phase 3 PhALLCON trial met its primary endpoint. Results demonstrated that adult patients with newly diagnosed Ph+ALL who received ponatinib plus low-intensity chemotherapy achieved a significantly higher rate of MRD-negative complete remission (CR) compared with those treated with imatinib plus low-intensity chemotherapy. According to published literature, MRD negativity is associated with improved long-term outcomes in these patients.

No new safety signals were observed in the trial. Data from this study will be discussed with regulatory authorities and shared with the scientific community in the future.

"Ph+ALL is an aggressive disease, and currently, no targeted therapy is approved as first-line treatment for patients in the United States. There is an urgent need for an effective therapeutic approach that can inhibit the development of treatment-resistant mutations, which are linked to poor long-term outcomes," stated Dr. Awny Farajallah, Head of Global Medical Affairs, Oncology at Takeda. "We are encouraged by how ponatinib addresses this gap in patient care and look forward to sharing the full results."

Mechanism of Action of Ponatinib

Ponatinib is a BCR-ABL1-targeted tyrosine kinase inhibitor (TKI). BCR-ABL1 is an abnormal tyrosine kinase expressed in chronic myeloid leukemia (CML) and Ph+ALL. As a targeted oncology agent developed through a computational and structure-based drug design platform, ponatinib is specifically engineered to inhibit the activity of BCR-ABL1 and its mutations. It exerts inhibitory effects on both native BCR-ABL1 and all BCR-ABL1 mutations that confer resistance to other TKIs, including the highly refractory T315I mutation.

Approved Indications of Ponatinib

Ponatinib received full approval from the U.S. Food and Drug Administration (FDA) in November 2016. It is indicated for the treatment of the following adult patient populations:

Patients with chronic-phase chronic myeloid leukemia (CP-CML) who are resistant or intolerant to at least two prior kinase inhibitors;

Patients with accelerated-phase (AP) or blast-phase (BP) CML, or Ph+ALL, for whom no other kinase inhibitors are available;

Patients with T315I mutation-positive CML (CP, AP, or BP) or T315I mutation-positive Ph+ALL.

Important Note: Ponatinib is not indicated and is not recommended for the treatment of patients with newly diagnosed CP-CML.